3.89
-0.17(-4.19%)
Currency In USD
| Previous Close | 4.06 |
| Open | 4.1 |
| Day High | 4.16 |
| Day Low | 3.87 |
| 52-Week High | 4.69 |
| 52-Week Low | 2.3 |
| Volume | 80,479 |
| Average Volume | 63,100 |
| Market Cap | 331.64M |
| PE | -7.48 |
| EPS | -0.52 |
| Moving Average 50 Days | 3.98 |
| Moving Average 200 Days | 3.26 |
| Change | -0.17 |
If you invested $1000 in Alpha Tau Medical Ltd. (DRTS) since IPO date, it would be worth $385.15 as of December 07, 2025 at a share price of $3.89. Whereas If you bought $1000 worth of Alpha Tau Medical Ltd. (DRTS) shares 3 years ago, it would be worth $1,045.7 as of December 07, 2025 at a share price of $3.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
GlobeNewswire Inc.
Dec 04, 2025 2:00 PM GMT
Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026JERUSALEM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS,
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
GlobeNewswire Inc.
Dec 02, 2025 2:00 PM GMT
- FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer -JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer o
Alpha Tau to Participate in December Investor Conferences
GlobeNewswire Inc.
Dec 01, 2025 2:00 PM GMT
JERUSALEM, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present